Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 15/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 15/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 14/20 | 0.40 |
| ▸ | PI4KA | P42356 | 2/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.39 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065452 | 0.85 | ADORA3 (0.56) | ADORA3ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL4059528 | 0.83 | ADORA3 (0.60) | ADORA3ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL4054756 | 0.75 | ADORA2A (0.68) | ADORA3ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL4057715 | 0.72 | ADORA3 (0.46) | ADORA3ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL4056955 | 0.72 | ADORA3 (0.76) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL4055180 | 0.71 | ADORA3 (0.73) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL4065331 | 0.71 | ADORA3 (0.73) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL17115737 | 0.67 | DAPK1 (0.78) | ADORA3ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL2310972 | 0.65 | CDK1 (0.58) | ADORA2AADORA1ADORA2BDAPK1KDM4E | |
| SCHEMBL3441095 | 0.63 | ADORA3 (0.47) | ADORA3ADORA2AADORA1ADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517888-B2 | e.g. cyclopentyl(9-ethyl-8-phenylpurin-6-yl)amine; diuretic; heart failure, chronic renal disease, cirrhosis | CV THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20050245546-A1 | A1 adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245546-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.